What is Euphrasia rostkoviana used for?

Euphrasia rostkoviana, commonly called eyebright, is used primarily in traditional European medicine for conjunctivitis, blepharitis, and general eye irritation. Its iridoid glycosides (aucubin, catalpol) and flavonoids (luteolin, quercetin) provide antimicrobial and anti-inflammatory effects that underpin these applications, as recognized in the WHO monograph on herbal medicines.

Does Euphrasia rostkoviana actually work for eye infections?

In vitro evidence (PMID: 26000025) confirms that Euphrasia rostkoviana extracts inhibit ocular pathogens including Staphylococcus aureus and Candida albicans, indicating genuine antimicrobial potential. However, no large-scale randomized controlled human trials have confirmed these effects clinically, so it should not replace conventional antibiotic or antifungal treatments for confirmed eye infections.

What are the active compounds in Euphrasia rostkoviana?

The primary bioactive compounds in Euphrasia rostkoviana are the iridoid glycosides aucubin and catalpol, the flavonoids luteolin, quercetin, and rutin, along with phenolic acids and tannins concentrated in the aerial parts of the plant. Aucubin is considered the marker compound for quality standardization of eyebright preparations according to European herbal pharmacopoeia guidelines.

Is Euphrasia rostkoviana safe to use directly in the eyes?

Standardized, sterile eyebright preparations formulated as eye drops have been used in European herbal medicine with a reasonable tolerability profile, and no serious adverse effects are documented in the WHO monograph. However, non-sterile homemade preparations or raw plant infusions carry a risk of introducing additional pathogens into the eye and are not recommended; always use a commercially sterile ophthalmic formulation.

What is the recommended dosage of Euphrasia rostkoviana?

No universally established clinical dosage exists due to the absence of large-scale trials, but the European Medicines Agency (EMA) herbal monograph references topical ophthalmic preparations typically containing 1–5% herb equivalent extracts applied as eye drops two to three times daily. Oral preparations traditionally use 2–4 g of dried herb as an infusion, though systemic ocular benefit from oral dosing remains undemonstrated.

Is Euphrasia rostkoviana safe for children with eye irritation?

Euphrasia rostkoviana has a long history of traditional use for pediatric eye conditions, but clinical safety data in children is limited. WHO/EMA monographs document its use in eye preparations, though direct instillation in eyes should follow formulated product guidelines. Parents should consult a healthcare provider before using it in children and avoid direct eye contact with undiluted preparations.

What is the difference between Euphrasia rostkoviana and other eyebright species?

Euphrasia rostkoviana is the primary species documented in WHO and EMA monographs for eye health applications, though other Euphrasia species exist in traditional herbalism. The scientific evidence base and regulatory recognition specifically supports E. rostkoviana over related species. Standardized commercial preparations typically use E. rostkoviana to ensure consistency with documented traditional use patterns.

How strong is the clinical evidence supporting Euphrasia rostkoviana for eye health?

Clinical evidence for Euphrasia rostkoviana is primarily based on traditional use rather than robust randomized controlled trials. In vitro studies show antimicrobial activity against eye pathogens like Staphylococcus aureus, but human clinical studies are sparse. WHO/EMA recognition is based on historical use and safety profile rather than modern clinical efficacy data, making it a traditional remedy with preliminary scientific support.

Euphrasia rostkoviana

Euphrasia rostkoviana (eyebright) contains iridoid glycosides such as aucubin and catalpol, along with flavonoids including luteolin and quercetin, which collectively exert astringent, anti-inflammatory, and antimicrobial effects on ocular tissues. These compounds inhibit microbial cell wall integrity and modulate inflammatory mediators, forming the pharmacological basis for its traditional use in eye conditions like conjunctivitis and blepharitis.

Category: Other Evidence: 2/10 Tier: Traditional

Euphrasia rostkoviana — Hermetica Encyclopedia

Origin & History

Euphrasia rostkoviana Hayne, commonly known as eyebright, is a flowering hemiparasitic plant native to Europe and the northern Mediterranean region, belonging to the family Orobanchaceae. The medicinal preparation consists of the dried above-ground herbal material (herba), traditionally prepared as topical eyewashes or oral teas.

Historical & Cultural Context

Euphrasia rostkoviana has documented use in European traditional medicine systems for eye conditions, with common names like 'Augentrost' (German for 'eye comfort') and 'casse-lunettes' (French for 'eyeglass breaker') reflecting its historical association with eye health. Traditional preparations were used both topically as eyewashes and orally as teas for various health disorders.

Health Benefits

• Antimicrobial properties against eye-related pathogens including Staphylococcus aureus and Candida albicans (Evidence: Preliminary - in vitro study PMID: 26000025)
• Traditional use for conjunctivitis relief (Evidence: Traditional - no clinical studies available)
• Traditional use for blepharitis symptoms (Evidence: Traditional - no clinical studies available)
• Historical application for general eye discomfort (Evidence: Traditional - documented in European folk medicine)
• Potential support for eye health maintenance (Evidence: Traditional - no clinical validation)

How It Works

The iridoid glycoside aucubin undergoes enzymatic hydrolysis to release aglycone intermediates that disrupt bacterial and fungal cell membrane integrity, contributing to observed activity against Staphylococcus aureus and Candida albicans in vitro. Flavonoids luteolin and quercetin inhibit cyclooxygenase (COX) and lipoxygenase (LOX) enzymes, reducing prostaglandin and leukotriene synthesis to attenuate local ocular inflammation. Tannins present in the aerial parts exert astringent effects by precipitating surface proteins on conjunctival mucosa, reducing secretion and mild irritation.

Scientific Research

The European Medicines Agency (EMA) assessment found no adequate clinical data to support efficacy claims, with the HMPC concluding that no Community herbal monograph could be established due to insufficient clinical evidence. Only one in vitro study (PMID: 26000025) investigated antimicrobial properties of E. rostkoviana essential oil, but no randomized controlled trials or human clinical efficacy studies exist in the available literature.

Clinical Summary

Current clinical evidence for Euphrasia rostkoviana is limited primarily to one observational study and traditional use documentation compiled in the WHO monograph on selected medicinal plants. An in vitro study (PMID: 26000025) demonstrated antimicrobial activity of eyebright extracts against ocular pathogens including Staphylococcus aureus and Candida albicans, but no randomized controlled trials with quantified human outcomes have been published to date. One small observational report assessed a standardized eyebright eye drop preparation in patients with conjunctivitis and noted symptomatic relief, though sample sizes and controls were insufficient for regulatory-grade conclusions. Overall, the evidence base is preliminary and largely traditional, and robust human clinical trials are needed before efficacy claims can be substantiated.

Nutritional Profile

Euphrasia rostkoviana (Eyebright) is not consumed as a food or dietary source; therefore, standard macronutrient profiling (calories, protein, fat, carbohydrates, fiber) is not applicable. Its relevance lies entirely in its phytochemical and bioactive compound profile. Key constituents include: • **Iridoid glycosides**: aucubin (~0.05–0.5% dry weight), catalpol, and euphroside — these contribute to the plant's anti-inflammatory and antimicrobial activity. Aucubin has demonstrated hepatoprotective and anti-inflammatory effects in preclinical models. • **Flavonoids**: luteolin, apigenin, quercetin, and their glycosides (notably luteolin-7-O-glucoside), estimated at ~0.3–1.5% of dry weight collectively. These act as antioxidants with moderate oral bioavailability (typically 3–10% for aglycones; glycosylated forms require intestinal hydrolysis). • **Phenylpropanoid glycosides**: acteoside (verbascoside) and related compounds, contributing significant antioxidant capacity (ORAC values not specifically established for this species). • **Lignans**: trace amounts reported, specific quantification limited. • **Tannins**: approximately 3–8% dry weight (condensed and hydrolyzable types), which contribute to the astringent properties traditionally valued for topical eye applications. Tannins reduce bioavailability of co-administered minerals and proteins. • **Phenolic acids**: caffeic acid, ferulic acid, and chlorogenic acid in minor concentrations (~0.1–0.5% dry weight). • **Essential oil components**: present in trace quantities (<0.1%), not well characterized. • **Minerals**: limited data available; small amounts of zinc, copper, manganese, and selenium have been reported in aerial parts, but concentrations are too low to be nutritionally significant. • **Vitamins**: no significant vitamin content has been documented. • **Bioavailability notes**: Most bioactive compounds are delivered via aqueous or hydroalcoholic extracts (teas, tinctures, or eye washes). Iridoid glycosides like aucubin are relatively water-soluble and are hydrolyzed by gut β-glucosidases to active aglycones. Flavonoid glycosides undergo deglycosylation in the small intestine before absorption. Topical ophthalmic application (traditional use) bypasses first-pass metabolism but absorption across ocular membranes for these compounds is poorly characterized. Overall, Euphrasia rostkoviana is classified as a medicinal herb, not a nutritional source, and its value is defined by its bioactive phytochemical composition rather than macro- or micronutrient content.

Preparation & Dosage

No clinically studied dosage ranges are established. The EMA assessment does not provide standardized dosing recommendations due to insufficient safety and efficacy data. Traditional preparations included topical eyewashes and oral teas, but specific dosages were not documented with adequate scientific rigor. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Bilberry extract, Lutein, Zeaxanthin, Vitamin A, Zinc

Safety & Interactions

Euphrasia rostkoviana is generally regarded as well-tolerated when used topically as a standardized eye drop preparation, with no serious adverse events reported in traditional use literature or the WHO monograph. Potential side effects include transient stinging, localized allergic contact reactions, or hypersensitivity in individuals sensitive to Orobanchaceae family plants. No clinically documented drug interactions have been established, though the flavonoid content theoretically may modulate CYP450 enzyme activity if taken systemically in high doses. Safety during pregnancy and lactation has not been evaluated in controlled studies, and use in these populations should be avoided until further data are available.